top of page

Servier's U.S. CEO discusses FDA approval of Voranigo, a targeted therapy for a common type of brain cancer

David Lee describes the glioma brain cancer population this IHD1/2 targeting therapy is for, Servier's experience commercializing cancer medicines, and how he thinks about deals going forward.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

SAV_Logo_2024.png

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

bottom of page